The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Spike mutation D614G alters SARS-CoV-2 fitness
Open accessPublished version of a preprint
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein substitution D614G became dominant during the coronavirus disease 2019 (COVID-19) pandemic 1,2. However, the effect of this variant on viral spread and vaccine efficacy remains to be defined. Here we engineered the spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral replication in human lung epithelial cells and primary human airway tissues by increasing the infectivity and stability of virions. Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. Sera from hamsters infected with D614 virus exhibit modestly higher neutralization titres against G614 virus than against D614 virus, suggesting that the mutation is unlikely to reduce the ability of vaccines in clinical trials to protect against COVID-19, and that therapeutic antibodies should be tested against the circulating G614 virus. Together with clinical findings, our work underscores the importance of this variant in viral spread and its implications for vaccine efficacy and antibody therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Jessica A et al. [26] studied replication kinetics of the D614G variant in human lung epithelial cell line Calu-3 and found 2.4-fold more infectious virus 36 hpi, indicating enhanced viral replication.”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [26]
In the citing paper
“One of the first identified variants includes the D614G mutation in the gene encoding the spike (S) protein, which enhances viral infectivity and shifts S protein conformation toward an angiotensin-converting enzyme 2 (ACE2)-binding fusion-competent state, without significantly modifying sensitivity to antibody neutralization 1,[6][7][8] .”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [7]
In the citing paper
“The D614G mutation is dominant in circulating strains around the world 7,8 .”
From Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera (2021) · cites this paper as [7]
In the citing paper
“The emergence of the common mutation N501Y from different geographical regions, as well as the previously emerged globally dominant D614G mutation, suggest that these mutations might improve viral fitness”
From Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera (2021) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
The New Statistics: Why and How
Cumming, G. (2014) · Psychological Science · doi:10.1177/0956797613504966 · Cited by 3,200
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Self-citationSARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.042 · Cited by 1,488
Research works printed but not linked: 1
- Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020). · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 1,008
Lin, Y.-C., Malott, R. J., Ward, L., Kiplagat, L., Pabbaraju, K., Gill, K., Berenger, B. M., Hu, J., Fonseca, K., Noyce, R. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09218-5 · Cited by 74
Could mutations of SARS-CoV-2 suppress diagnostic detection?
Ascoli, C. A. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00845-3 · Cited by 74
Akkız, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.636532 · Cited by 74
Mutational and phylogenetic analyses of the two lineages of the Omicron variant
Majumdar, S., & Sarkar, R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27558 · Cited by 71
Origin and evolution of SARS-CoV-2
Pagani, I., Ghezzi, S., Alberti, S., Poli, G., & Vicenzi, E. (2023) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-023-03719-6 · Cited by 85
SARS-CoV-2: is there neuroinvasion?
McQuaid, C., Brady, M., & Deane, R. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00267-y · Cited by 72
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72
Self-citationImmunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
Solforosi, L., Kuipers, H., Jongeneelen, M. A. C., Huber, S. K. R., van der Lubbe, J. E. M., Dekking, L., Czapska-Casey, D. N., Gil, A. I., Baert, M. R. M., Drijver, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202756 · Cited by 73
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 62
Self-citationBollavaram, K., Leeman, T., Lee, M. W., Kulkarni, A., Upshaw, S. G., Yang, J., Song, H. W., & Platt, M. O. (2021) · Protein Science · doi:10.1002/pro.4073 · Cited by 69
Xue, S., Han, Y., Wu, F., & Wang, Q. (2024) · Protein & Cell · doi:10.1093/procel/pwae007 · Cited by 81
Brufau, S. R., Chopra, A., Ryu, A. J., Gel, E. S., Raskar, R., Kremers, W. K., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1087 · Cited by 71
Quadeer, A. A., Ahmed, S. F., & McKay, M. R. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100312 · Cited by 71
COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern
Zeyaullah, M., AlShahrani, A. M., Muzammil, K., Ahmad, I., Alam, S., Khan, W. H., & Ahmad, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.693916 · Cited by 74
Goethem, N. V., Chung, P. Y. J., Meurisse, M., Vandromme, M., Mot, L. D., Brondeel, R., Stouten, V., Klamer, S., Cuypers, L., Braeye, T., et al. (2022) · Viruses · doi:10.3390/v14061297 · Cited by 69
Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains
Qing, E., Kicmal, T., Kumar, B., Hawkins, G. M., Timm, E. C., Perlman, S. M., & Gallagher, T. (2021) · mBio · doi:10.1128/mbio.01590-21 · Cited by 70
ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
Chen, Y., Zhang, Y., Yan, R., Wang, G., Zhang, Y., Zhang, Z., Li, Y., Ou, J., Chu, W., Liang, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00740-y · Cited by 68
Hematological changes associated with COVID‐19 infection
Al‐Saadi, E. A. K. D., & Abdulnabi, M. A. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24064 · Cited by 74
SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review
Mendiola-Pastrana, I. R., López‐Ortiz, E., de la Loza-Zamora, J. G. R., González, J., Gómez‐García, A., & López-Ortiz, G. (2022) · Life · doi:10.3390/life12020170 · Cited by 69
Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution
Ma, W., Fu, H., Jian, F., Cao, Y., & Li, M. (2023) · Nature Ecology & Evolution · doi:10.1038/s41559-023-02123-8 · Cited by 66
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lü, X., Yang, Z., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00985-w · Cited by 74
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Tanaka, S., Nelson, G., Olson, C. A., Buzko, O. V., Higashide, W., Shin, A., Gonzalez, M. R., Taft, J. D., Patel, R. S., Buta, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91809-9 · Cited by 65
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55
Self-citationMutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern
Shahhosseini, N., Babuadze, G. G., Wong, G., & Kobinger, G. (2021) · Microorganisms · doi:10.3390/microorganisms9050926 · Cited by 66
Possible Use of Phytochemicals for Recovery from COVID-19-Induced Anosmia and Ageusia
小山, 幸., Kondo, K., Ueha, R., Kashiwadani, H., & Heinbockel, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168912 · Cited by 66
Yang, T., Yu, P., Chang, Y., Kuo, C., Khoo, K., & Hsu, S. D. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101238 · Cited by 63
SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 68
The impact of oxidative stress damage induced by the environmental stressors on COVID-19
Bakadia, B. M., Boni, B. O. O., Ahmed, A. A. Q., & Yang, G. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118653 · Cited by 66
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 65
B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies
Zhan, Y., Yin, H. Y., & Yin, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66881 · Cited by 68
SARS-CoV-2 down-regulates ACE2 through lysosomal degradation
Lu, Y., Zhu, Q., Fox, D., Gao, C., Stanley, S. A., & Luo, K. (2022) · Molecular Biology of the Cell · doi:10.1091/mbc.e22-02-0045 · Cited by 66
Chan, L., Anderson, D. E., Cheng, H. S., Ivan, F. X., Chen, S., Zheng, A. K. E., Foo, R., Gamage, A. M., Tiew, P. Y., Koh, M. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35253-x · Cited by 72
Multiplexed detection of viral antigen and RNA using nanopore sensing and encoded molecular probes
Ren, R., Cai, S., Fang, X., Wang, X., Zhang, Z., Damiani, M., Hudlerova, C., Rosa, A., Hope, J., Cook, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43004-9 · Cited by 69
Chua, G. T., Wong, J. S. C., Lam, I. C. S., Ho, P. K., Chan, W. H., Yau, F. Y. S., Duque, J. S. R., Ho, A. C. C., Siu, K. K., Cheung, T. W. Y., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8824 · Cited by 64
Yoon, T., Shin, J., Choi, H., & Park, K. S. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114221 · Cited by 64
Souza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Belém, M. O., Pinto, Y. O., Moreira, H. H. T., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.058 · Cited by 67
Li, J., Zhang, Z., Gu, J., Amini, R., Mansfield, A., Xia, J., White, D., Stacey, H. D., Ang, J. C., Panesar, G., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09870 · Cited by 65
Verkhivker, G. M., & Paola, L. D. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c10637 · Cited by 56
Neurotropic Viruses, Astrocytes, and COVID-19
Verdev, P. T., Potokar, M., Kolenc, M., Korva, M., Avšič‐Županc, T., Zorec, R., & Jorgačevski, J. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.662578 · Cited by 72
Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding
Yang, L., Chen, R. H., Hamdoun, S., Coghi, P. S., Ng, J. P. L., Zhang, D. W., Guo, X., Xia, C., Law, B. Y. K., & Wong, V. K. W. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153591 · Cited by 68
Dan, T. N., Donckers, K., Vangeel, L., Chatterjee, A. K., Gallay, P. A., Bobardt, M. D., Bilello, J. P., Cihlář, T., Jonghe, S. D., Neyts, J. H., et al. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105122 · Cited by 61
Self-citationChronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice
Vidal, E., López-Figueroa, C., Rodon, J., Pérez, M., Brustolin, M., Cantero, G., Guallar, V., Izquierdo‐Useros, N., Carrillo, J., Blanco, J., et al. (2021) · Veterinary Pathology · doi:10.1177/03009858211066841 · Cited by 61
Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection
Letarov, A. V., Babenko, V. V., & Kulikov, E. E. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297921030032 · Cited by 66
Mohammad, T., Choudhury, A., Habib, I., Asrani, P., Mathur, Y., Umair, M., Anjum, F., Shafie, A., Yadav, D. K., & Hassan, M. I. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.765039 · Cited by 61
Rapid and accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform
He, C., Lin, C., Mo, G., Xi, B., Li, A., Huang, D., Wan, Y., Chen, F., Liang, Y., Zuo, Q., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113857 · Cited by 61
Banho, C. Á., Sacchetto, L., Campos, G. R. F., Bittar, C., Possebon, F. S., Ullmann, L. S., Marques, B. D. C., da Silva, G. C. D., Moraes, M. M., Parra, M. C. P., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00108-5 · Cited by 63
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
Alkhatib, M., Svicher, V., Salpini, R., Ambrosio, F. A., Bellocchi, M. C., Carioti, L., Piermatteo, L., Scutari, R., Costa, G., Artese, A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01096-21 · Cited by 62
Banach, B. B., Cerutti, G., Fahad, A. S., Shen, C., de Souza, M. O., Katsamba, P. S., Tsybovsky, Y., Wang, P., Nair, M. S., Huang, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109771 · Cited by 56
Antigenic characterization of influenza and SARS-CoV-2 viruses
Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 62
The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype
Barut, G. T., Halwe, N. J., Taddeo, A., Kelly, J. N., Schön, J., Ebert, N., Ulrich, L., Devisme, C., Steiner, S., Trüeb, B. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33632-y · Cited by 56
SARS-CoV-2: vaccines in the pandemic era
Li, D., & Li, Q. (2021) · Military Medical Research · doi:10.1186/s40779-020-00296-y · Cited by 61
Development and application of therapeutic antibodies against COVID-19
Lin, N., Abagna, H. B., Jiang, Q., Liu, S., & Huang, J. H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59149 · Cited by 61
SARS-CoV-2 replicates in respiratory ex vivo organ cultures of domestic ruminant species
Teodoro, G. D., Valleriani, F., Puglia, I., Monaco, F., Pancrazio, C. D., Luciani, M., Krasteva, I. M., Petrini, A., Marcacci, M., D’Alterio, N., et al. (2020) · Veterinary Microbiology · doi:10.1016/j.vetmic.2020.108933 · Cited by 56
Brosey, C. A., Houl, J. H., Katsonis, P., Balapiti-Modarage, L. P. F., Bommagani, S., Arvai, A., Moiani, D., Bacolla, A., Link, T. M., Warden, L. S., et al. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.02.002 · Cited by 60
SARS-CoV-2 variants reveal features critical for replication in primary human cells
Pohl, M. O., Busnadiego, I., Kufner, V., Glas, I., Karakus, U., Schmutz, S., Zaheri, M., Abela, I. A., Trkola, A., Huber, M., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001006 · Cited by 55
Cheng, M. H., Krieger, J., Kaynak, B., Arditi, M., & Bahar, İ. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.10.426143 · Cited by 57
SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
Dao, T. L., Hoang, V. T., Colson, P., Lagier, J., Million, M., Raoult, D., Levasseur, A., & Gautret, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122635 · Cited by 61
López, M. G., Chiner‐Oms, Á., de Viedma, D. G., Ruiz-Rodríguez, P., Bracho, M. A., Cancino‐Muñoz, I., D’Auria, G., Marco, G. D., García‐González, N., Goig, G. A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00936-6 · Cited by 56
Emerging SARS-CoV-2 variants: Why, how, and what's next?
Chen, Y. Z., Liu, Q., Zhou, L., Zhou, Y., Yan, H., & Lan, K. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100029 · Cited by 58
Kang, Y., Sun, C., Sun, J., Xie, C., Zhuang, Z., Xu, H.-Q., Liu, Z., Liu, Y., Peng, S., Yuan, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30222-w · Cited by 56
Self-citationUnderstanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis
Kumar, R., Srivastava, Y., Muthuramalingam, P., Singh, S. K., Verma, G., Tiwari, S., Tandel, N., Beura, S. K., Panigrahi, A. R., Maji, S., et al. (2023) · Viruses · doi:10.3390/v15040856 · Cited by 57
The evolutionary dynamics of endemic human coronaviruses
Jo, W. K., Drosten, C., & Drexler, J. F. (2021) · Virus Evolution · doi:10.1093/ve/veab020 · Cited by 60
Genomic Epidemiology of the First Wave of SARS-CoV-2 in Italy
Giallonardo, F. D., Duchêne, S., Puglia, I., Curini, V., Profeta, F., Cammà, C., Marcacci, M., Calistri, P., Holmes, E. C., & Lorusso, A. (2020) · Viruses · doi:10.3390/v12121438 · Cited by 56
The origin of human mutation in light of genomic data
Seplyarskiy, V. B., & Sunyaev, S. R. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00376-2 · Cited by 58
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
Ma, M. T., Badeti, S., Chen, C.-H., Kim, J., Choudhary, A. K., Honnen, B., Reichman, C., Calianese, D. C., Pinter, A., Jiang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652223 · Cited by 54
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 54
Lu, M., Chamblee, M., Zhang, Y., Ye, C., Dravid, P., Park, J., Mahesh, K., Trivedi, S., Murthy, S. S., Sharma, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110105119 · Cited by 55
Spike Glycoprotein-Mediated Entry of SARS Coronaviruses
Wang, L., & Xiang, Y. (2020) · Viruses · doi:10.3390/v12111289 · Cited by 51
The SARS-CoV-2 spike protein is vulnerable to moderate electric fields
Arbeitman, C. R., Rojas, P., Ojeda-May, P., & Garcia, M. E. (2021) · Nature Communications · doi:10.1038/s41467-021-25478-7 · Cited by 54
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
Marsh, G. A., McAuley, A. J., Au, G. G., Riddell, S. J., Layton, D., Singanallur, N. B., Layton, R., Payne, J., Durr, P. A., Bender, H. S., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00315-6 · Cited by 53
Mechanical activation of spike fosters SARS-CoV-2 viral infection
Hu, W., Zhang, Y., Fei, P., Zhang, T., Yao, D., Gao, Y., Liu, J., Chen, H., Qiao, L., Mudianto, T., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00558-x · Cited by 52
Self-citationCOVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Maisonnasse, P., Aldon, Y., Marc, A., Marlin, R., Dereuddre‐Bosquet, N., Kuzmina, N. A., Freyn, A. W., Snitselaar, J. L., Gonçalves, A., Caniels, T. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26354-0 · Cited by 59
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 55
Pal, A., Ganguly, A., Wei, P., Barman, S. R., Chang, C., & Lin, Z. (2023) · Advanced Science · doi:10.1002/advs.202307266 · Cited by 53
Computationally restoring the potency of a clinical antibody against Omicron
Desautels, T., Arrildt, K. T., Zemla, A. T., Lau, E. Y., Zhu, F., Ricci, D. P., Cronin, S., Zost, S. J., Binshtein, E., Scheaffer, S. M., et al. (2024) · Nature · doi:10.1038/s41586-024-07385-1 · Cited by 51
Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach
González‐Parra, G., Martínez‐Rodríguez, D., & Villanueva, R. J. (2021) · Mathematical and Computational Applications · doi:10.3390/mca26020025 · Cited by 55
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy
Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 51
Chemical design principles of next-generation antiviral surface coatings
Wang, N., Ferhan, A. R., Yoon, B. K., Jackman, J. A., Cho, N., & Majima, T. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00317h · Cited by 52
The molecular basis for SARS-CoV-2 binding to dog ACE2
Zhang, Z., Zhang, Y., Liu, K., Li, Y., Lu, Q., Wang, Q., Zhang, Y., Wang, L., Liao, H., Zheng, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24326-y · Cited by 52
SARS-CoV-2 in residential rooms of two self-isolating persons with COVID-19
Shankar, S. N., Witanachchi, C. T., Morea, A. F., Lednicky, J. A., Loeb, J. C., Alam, M. M., Fan, Z. H., Eiguren-Fernandez, A., & Wu, C. (2021) · Journal of Aerosol Science · doi:10.1016/j.jaerosci.2021.105870 · Cited by 52
SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.777212 · Cited by 52
Yoon, J., Conley, B. M., Shin, M., Choi, J., Bektas, C. K., Choi, J., & Lee, K. (2022) · ACS Nano · doi:10.1021/acsnano.1c10824 · Cited by 52
Wang, L., Kainulainen, M. H., Jiang, N., Di, H., Bonenfant, G., Mills, L. A., Currier, M., Shrivastava-Ranjan, P., Calderon, B. M., Sheth, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31929-6 · Cited by 51
Self-citationAsymptomatic COVID‐19: disease tolerance with efficient anti‐viral immunity against SARS‐CoV‐2
Chan, Y., Fong, S., Poh, C. M., Carissimo, G., Yeo, N. K., Amrun, S. N., Goh, Y. S., Lim, J., Xu, W., Chee, R. S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114045 · Cited by 50
The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant
Kimura, I., Yamasoba, D., Nasser, H., Zahradník, J., Kosugi, Y., Wu, J., Nagata, K., Uriu, K., Tanaka, Y., Ito, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105720 · Cited by 50
Genetic emergence of B.1.617.2 in COVID-19
Kirola, L. (2021) · New Microbes and New Infections · doi:10.1016/j.nmni.2021.100929 · Cited by 51
D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity
Bhattacharya, M., Chatterjee, S., Sharma, A. R., Agoramoorthy, G., & Chakraborty, C. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11676-2 · Cited by 55
SARS-CoV-2 Variant Screening Using a Virus-Receptor-Based Electrical Biosensor
Park, S., Kim, H., Woo, K., Kim, J., Jo, H. J., Jeong, Y., & Lee, K. H. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03108 · Cited by 51
Gale, P. (2021) · Microbial Risk Analysis · doi:10.1016/j.mran.2021.100198 · Cited by 51
Kim, H. K., Cho, J., Kim, E., Kim, J., Yang, J., Kim, K.-C., Lee, J., Shin, Y., Palomera, L. F., Park, J., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12179 · Cited by 50
Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics
Kudriavtsev, A. V., Vakhrusheva, A., Novoseletsky, V. N., Bozdaganyan, M. E., Шайтан, К. В., Kirpichnikov, M. P., & Sokolova, O. S. (2022) · Viruses · doi:10.3390/v14081603 · Cited by 52
SARS-CoV-2 evolution influences GBP and IFITM sensitivity
Mesner, D., Reuschl, A., Whelan, M. V. X., Bronzovich, T., Haider, T., Thorne, L., Ragazzini, R., Bonfanti, P., Towers, G. J., & Jolly, C. L. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212577120 · Cited by 54
An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection
Mei, X., Li, J., Wang, Z., Zhu, D., Huang, K., Hu, S., Popowski, K. D., & Cheng, K. (2023) · Nature Materials · doi:10.1038/s41563-023-01475-7 · Cited by 53
The Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense
Azgari, C., Kilinç, Z., Turhan, B., Çırcı, D., & Adebalı, O. (2021) · Viruses · doi:10.3390/v13030394 · Cited by 47
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
Brustolin, M., Rodon, J., de la Concepción, M. L. R., Ávila‐Nieto, C., Cantero, G., Pérez, M., Te, N., Noguera-Julián, M., Guallar, V., Valencia, A., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1913974 · Cited by 50
The challenges of COVID‐19 Delta variant: Prevention and vaccine development
He, X., He, C., Hong, W., Zhang, K., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.95 · Cited by 52
Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures
Shao, W., Zhang, W., Fang, X., Yu, D., & Wang, X. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.03.007 · Cited by 50
SARS-CoV-2: phenotype, genotype, and characterization of different variants
Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 56
Khatri, R., Siddqui, G., Sadhu, S., Maithil, V., Vishwakarma, P., Lohiya, B., Goswami, A., Ahmed, S., Awasthi, A., & Samal, S. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00760-7 · Cited by 55
Huang, S., & Wang, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063060 · Cited by 50
Metadata
- Authors
- Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., Mirchandani, D., Scharton, D., Bilello, J. P., Ku, Z., An, Z., Kalveram, B., Freiberg, A. N., Menachery, V. D., Xie, X., Plante, K. S., Weaver, S. C., & Shi, P.-Y.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Gilead Sciences (United States) (US)
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- Corresponding author
- Xie, Xuping
- Plante, Kenneth S.
- Weaver, Scott C.
- Shi, Pei-Yong
- ORCID
- Venue
- Nature
- Published
- 2020-10-26
- Volume
- 592
- Issue
- 7852
- Pages
- 116-121
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8158177
- OpenAlex
- W3093768302
- Cited by
- 1,558
- References
- 37
- Citations by year
- 2026: 37 · 2025: 73 · 2024: 120 · 2023: 174 · 2022: 427 · 2021: 670 · 2020: 55
- FWCI
- 43.60
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-06-15)
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Amon G. Carter Foundation
- John S. Dunn Foundation (AI145617)
- University of Texas System
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (AI134907)
- National Institutes of Health (AG049042, TL1TR001440, AI145617, AI142759, UL1TR001439)
- National Institute on Aging (AI142759, AG049042, R00AG049092)
- National Institute of Allergy and Infectious Diseases (R43AI145617, AI142759, R24AI120942, R01AI134907, R21AI145400, U01AI151801, U19AI142759, R01AI153602, AI153602, AG049042, AI134907, AI145617, UC7AI094660)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, viral fitness, viral replication, upper respiratory tract infection, virus transmission, neutralizing antibodies, vaccine efficacy, hamster model, lung epithelial cells, therapeutic antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
